Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM2 | Q00987 | 6/20 | 0.54 |
| ▸ | TLR2 | O60603 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | MDM4 | O15151 | 2/20 | 0.51 |
| ▸ | TP53 | P04637 | 2/20 | 0.51 |
| ▸ | CASP3 | P42574 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25357584 | 0.92 | MDM2 (0.56) | MDM2TLR2KMT2AMDM4TP53 | |
| SCHEMBL25357589 | 0.92 | MDM2 (0.56) | MDM2TLR2KMT2AMDM4TP53 | |
| SCHEMBL18148920 | 0.90 | KMT2A (0.64) | MDM2TLR2KMT2AMDM4TP53 | |
| SCHEMBL29401604 | 0.90 | KMT2A (0.64) | MDM2TLR2KMT2AMDM4TP53 | |
| SCHEMBL119708 | 0.90 | KMT2A (0.64) | MDM2TLR2KMT2AMDM4TP53 | |
| SCHEMBL119709 | 0.90 | KMT2A (0.64) | MDM2TLR2KMT2AMDM4TP53 | |
| SCHEMBL29423590 | 0.90 | KMT2A (0.64) | MDM2TLR2KMT2AMDM4TP53 | |
| SCHEMBL14583977 | 0.90 | MDM2 (0.53) | MDM2TLR2KMT2AMDM4TP53 | |
| SCHEMBL29829454 | 0.90 | MDM2 (0.53) | MDM2TLR2KMT2AMDM4TP53 | |
| SCHEMBL12214738 | 0.90 | MDM2 (0.53) | MDM2TLR2KMT2AMDM4TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110319592-A1 | Process for the Purification of Antibodies Using Affinity Resins Comprising Specific Ligands | NOVO NORDISK A/S (DK) | 2011-12-29 | — | — | US | disclosed |
| US-20100113519-A1 | 1,5-Dideoxy-1,5-imino-D-glucitol Compounds | ACADEMIA SINICA (TW) | 2010-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110319592-A1 | Process for the Purification of Antibodies Using Affinity Resins Comprising Specific Ligands | FCGR1A, FCGR2A, FCGR3B | MDM2 3907/4885TLR2 2269/4885KMT2A 1878/4885 |
| US-20100113519-A1 | 1,5-Dideoxy-1,5-imino-D-glucitol Compounds | HEXD, GALE, GBA1 | MDM2 4217/4885TLR2 3749/4885KMT2A 4450/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.